|
|
Post by trenddiver on Dec 8, 2015 19:02:30 GMT -5
Because of the rules governing material non-public information, insiders at Mannkind are not buying stock at this time (except for Mannkind's employee stock purchase plans). Trend Trend: I don't think you have it right. Insiders can buy stock in the open market as long as their purchases are not based on non-public information. Stock Purchase Plans are used so that the insider has a clear defense against others claiming that their Like you said its "risky". Because Mannkind has not disclosed significant stuff going on behind the scenes with both Afrezza and Technosphere, all the knowledge and information they possess could be characterized as material non-public information. Thus, it's unlikely they would feel comfortable purchasing stock on the open market other than in preapproved employee stock purchase plans. They were already spanked pretty hard in the past because of a previous class action lawsuit so I imagine they are not taking any unnecessary chances. Trend |
|
|
|
Post by trenddiver on Dec 8, 2015 13:38:12 GMT -5
I'm sure they are seriously questioning Sanofi's game plan, but I don't think sandbagging is their concern. Big Al or his proxies will weigh in at the JAC meeting this week and hopefully will be demanding significantly more resources devoted to Afrezza in addition to lower prices and tv advertising. Trend OK, I'll buy that, but then if they truly do not have any concerns about Sanofi's commitment, wouldn't the current situation be something they already discussed and knew about? Or did management in Mannkind completely washed their hands and just went along for the ride agreeing with everything Sanofi threw at them, just now realizing that maybe they should have been a bit more involved. The short answer is YES. |
|
|
|
Post by trenddiver on Dec 8, 2015 13:36:49 GMT -5
Serious question though, is there an event that could restrict insider buying or a SNY buy in for a period of time? I don't know enough about insider buying laws but example being, and this is probably a ridiculous view but: If MNKD and SNY agreed on a buyout for Afrezza 6 months ago with the intention of announcing in 2016, are there restrictions with insider buying, basically I'm asking if they wouldn't be able to buy at these low levels because of an "event" that is pending. I am not an expert, however, my understanding is an insider (i.e. Al Mann) can buy stock in the open market as long as it's not based on non-public information and that the insider (or purchaser of over 5%) provides proper legal notice in accordance with SEC laws. In other words, insiders could be buying stock today (but I have no information that they are just in case jpg take exception to my post!) Because of the rules governing material non-public information, insiders at Mannkind are not buying stock at this time (except for Mannkind's employee stock purchase plans). Trend |
|
|
|
Post by trenddiver on Dec 8, 2015 13:27:29 GMT -5
I wonder if Al & MNKD "feel" that SNY is sand bagging Afrezza? Would really like to know how they feel about the partnership right now. I'm sure they are seriously questioning Sanofi's game plan, but I don't think sandbagging is their concern. Big Al or his proxies will weigh in at the JAC meeting this week and hopefully will be demanding significantly more resources devoted to Afrezza in addition to lower prices and tv advertising. Trend |
|
|
|
Post by trenddiver on Dec 7, 2015 23:47:59 GMT -5
The one thing I'd most like to know is how many users attended. Maybe, someone credible will leak that amount of info. If it is only a handful, I wouldn't put that much importance on it. If it was a fairly large gathering then maybe it plays into a scenario whereby SNY's apparent inaction has been waiting for sufficiently large number of users to provide critical feedback on diets and dosing to allow SNY, along with their physician advisory board, to construct protocols for a new set of trials proving superiority. I hope, I hope. Now we shall all have a mandatory sing along of Somewhere Over the Rainbow. The issue with a "leak" is everything that is shared on YMB and maybe here is going to probably claim "leaked info", it's a slippery slope that I am not willing to slide believing these rumors which have been false time and time again. We would need any "rumor" or "leak" to be vouched for by someone in the know and as we know [or speculate] anyone in the know has [likely] signed an NDA(?). Optimistically I'm thinking this meeting may have been SNY collecting preliminary info from first adopters - but to what end? We will not know until it plays out... its like the vicious circle of information gathering with this stock, it's almost funny. We are like in the fifth level of inception and are left to speculate on past speculation which probably came about through earlier speculation now accepted as fact. So once again, optimistically - speculating - this meeting is extremely important and a BIG step in SNY's showing of commitment - when do we see the effects from it in the form of Rx#s before it's just written off as another hyped up non-event? This is why I don't like to speculate on anything anymore, it's like a labrynth of "if this, then what" that becomes an entangled web of craziness and "happy" thoughts run wild which is impossible to navigate, then somewhere down the rabbit hole we start discussing 1300% eminent stock increases which are to be caused by unknown future circumstance.  Sorry I know that was just a cluster&%$k of thoughts and words, too late for MNKD, time to retire for the night.  Jeremg. I totally understand your frustration and after reading your last post all I can say is that you're way too hooked into the "balance of the day" for your own sanity. Hopefully this investment isn't such a large part of your net worth that it would devastating should it not work out. If it is that significant - your probably in too deep! If it's not that material, I suggest you take off a copy of weeks off from this addictive board and come back after New Years. What you'll find is that things will pretty will be the same and your stress level will be much less. Happy holidays Trend |
|
|
|
Post by trenddiver on Dec 7, 2015 23:16:26 GMT -5
I'd love to be a fly on the wall. Maybe after meeting, we'll hear something from SNY or MNKD. It certainly would be interesting if Al showed up. Trend did you get invitation to the meeting or was it published? Invitation only. |
|
|
|
Post by trenddiver on Dec 7, 2015 13:39:36 GMT -5
I'd love to be a fly on the wall. Maybe after meeting, we'll hear something from SNY or MNKD. It certainly would be interesting if Al showed up.
Trend
|
|
|
|
Post by trenddiver on Dec 6, 2015 14:00:19 GMT -5
DBC, Sanofi's strategy re pricing has been well discussed and explained in many excellent posts on this board. We will know at some point whether it was the best strategy because worldwide pricing (and Afrezza revenue) to a large extent, is based on the U.S. pricing. Mannkind entrusted Afrezza to Sanofi, because Sanofi was arguably the leader in the diabetes genre to launch the product. I remember when the Sanofi deal was announced how ecstatic most on this board were to have such an outstanding partner. Now, many of those same posters (most of whom have launched nothing) question or disagree with the pricing and launch strategy and Sanofi's commitment. Of course we worry about the effect on MNKD, the share price and the current lack of revenue, hence cash burn. However, Mannkind should have prepared for the launch strategy by creating sufficient capital to weather the launch. Unfortunately our management was drinking the Kool-Aid and did not plan for the headwinds by raising additional capital at higher prices. As a long term shareholder of MNKD, I want Sanofi to continue proceeding in a way that will best exploit the potential of Mannkind over the longterm for that is the best way to create long term shareholder value. At this point in time all we long shareholders can do is buy at these depressed prices if we believe that the future will be better, or do nothing or even sell if we have no confidence in the plan. But whining and complaining on this board will do nothing (I direct this comment to no one specifically.) Like I said in other posts, I'm buying. Trend I think rather than explained, you meant speculated on. None of us know why SNY has made the decisions they have made. I tend to believe that SNY has a strategy that will maximize long term benefit to them, if not me... but that is speculation. We have no way of knowing what goes on behind the curtain... what was expected vs what has happened and what is still to come. Seriously speaking, do you think Sanofi and/or Mannkind should be discussing its pricing and other business strategies especially when ongoing sensitive insurance negotiations are ongoing? I think not. |
|
|
|
Post by trenddiver on Dec 6, 2015 2:12:30 GMT -5
I think anything under $2.00 is a great value.
|
|
|
|
Post by trenddiver on Dec 6, 2015 1:44:06 GMT -5
trenddiver ... I don't think we'll ever ever know whether it was the best strategy... I just hope a workable strategy regarding MNKD shareholders. DBC, Sanofi's strategy re pricing has been well discussed and explained in many excellent posts on this board. We will know at some point whether it was the best strategy because worldwide pricing (and Afrezza revenue) to a large extent, is based on the U.S. pricing. Mannkind entrusted Afrezza to Sanofi, because Sanofi was arguably the leader in the diabetes genre to launch the product. I remember when the Sanofi deal was announced how ecstatic most on this board were to have such an outstanding partner. Now, many of those same posters (most of whom have launched nothing) question or disagree with the pricing and launch strategy and Sanofi's commitment. Of course we worry about the effect on MNKD, the share price and the current lack of revenue, hence cash burn. However, Mannkind should have prepared for the launch strategy by creating sufficient capital to weather the launch. Unfortunately our management was drinking the Kool-Aid and did not plan for the headwinds by raising additional capital at higher prices. As a long term shareholder of MNKD, I want Sanofi to continue proceeding in a way that will best exploit the potential of Mannkind over the longterm for that is the best way to create long term shareholder value. At this point in time all we long shareholders can do is buy at these depressed prices if we believe that the future will be better, or do nothing or even sell if we have no confidence in the plan. But whining and complaining on this board will do nothing (I direct this comment to no one specifically.) Like I said in other posts, I'm buying. Trend |
|
|
|
Post by trenddiver on Dec 5, 2015 1:56:53 GMT -5
Here is what my father, a retired orthopedic surgeon and very heavily invested MNKD long, discovered from speaking with his friend, a local pharmacist: The relative wholesale cost of pen injected Humalog vs. Afrezza (which the pharmacist had never even heard of) was $1.12 for Humalog and $2.50 for Afrezza, comparing 4 units of each. Has anyone on this board investigated this issue? If the reported information is correct, is there any wonder why Afrezza is not being covered by insurance and why it isn't selling as we expected? We were told by MNKD's management that Afrezza was to be priced competitively with insulin pens. Why would they say that if they knew that Sanofi was intending to make it more than twice as expensive? Is Sanofi breaching its contractual obligation with MNKD by pricing Afrezza so high? I'm not looking for any speculation here, but if someone knows something relevant to this issue, I'd love to hear it. Someone can correct me if I am wrong, but statements I am aware of from MNKD saying that were before the SNY deal was inked. No, I would highly doubt there is a minimum pricing in the agreement that SNY is ignoring. I would assume the pricing was set by the committee... of course SNY would win if there was a disagreement because the agreement does give them that power. From MNKD's prior statements we can presume that SNY either convinced MNKD of this strategy or simply used their override vote. I do agree that it would be nice if MNKD were to at least acknowledge that the pricing has turned out to be different even if they couldn't give the reasoning... but whose kidding whom, that ain't going to happen. Back in summer I thought the high price was because they felt they were in a strong enough position to quickly prove that they deserved a premium price. Of course now I tend to think everything I think must be wrong... but it's hard to figure out when to stop that circular reasoning. Though one note: The pens also require needle which are supposed to only be used once. Further, Afrezza price is not based on units so a 12u is not 3x a 4u. The overall cost for difference for payers is thus not likely to be as high as the original data for this thread would imply... but Afrezza is still meaningfully more. I suspect what happened with the pricing was that Mannkind deferred to Sanofi's on the pricing because they believed that Sanofi's had the expertise and theoretically knew what they were doing. We won't know for a few months whether in the long run it was the best strategy. Hopefully it will be thoroughly discussed at the next JAC meeting. Trend |
|
|
|
Post by trenddiver on Dec 4, 2015 20:25:54 GMT -5
jeremg also, Does mnkd want to be a product development company, or an Afrezza production company. The wisest move might be to separate the two so that everyone knows their jobs. Human insulin by Technospere was quite a triumph. The smaller molecules or peptides should be a cake walk, so why haven't we seen any? One reason I can think of to keep the two together is so MNKD can use Afrezza milestone payments and profits to fund TS developments. If they were separated the MNKD TS company would lose its primary source of funding for TS developments. Without funding, there are no TS products. New capital will be raised to exploit the TS opportunities in a spunoff entity, I think that would be the preferred strategy going forward. |
|
|
|
Post by trenddiver on Dec 4, 2015 14:41:54 GMT -5
I got 100 Jan 2017 3 calls. And 50 2017 2.50 Consider the 2018 $5 calls; last traded for 45 cents. I think very expensive compared to the share price of $1.94 |
|
|
|
Post by trenddiver on Dec 4, 2015 14:40:09 GMT -5
Just bought 5000 sh at 1.9389
Trend
|
|
|
|
Post by trenddiver on Dec 4, 2015 12:39:12 GMT -5
I'm not sure that is factual, but negotiations maybe occurring sooner than you think. The likelihood part implied that I didn't think it a provable fact. I suppose it also depends on what is meant by "negotiations". We know there is a board that directs the Afrezza JV, and I'm sure there would always be some issues where MNKD and SNY don't see eye to eye... though we know SNY has the final word in case of disagreement. That said, we have no indication that there is any significant disagreement that has arisen between MNKD and SNY. MNKD has stated that they are happy with SNY's efforts. It is nothing but speculation that any other "negotiation" would be taking place... buy-out of MNKD, dissolution of agreement, etc. etc. But yes, there indeed "maybe" some huge deal be brokered now or "soon" in the future. I'll stick by our respective choices of wording that such negotiation "maybe" possible but "in all likelihood" is not occurring. I don't think we will be seeing any significant change in the relationship between MNKD and SNY... though hopefully SNY's plan will be playing out in a more visible way, such as some action regarding new trials after this SD advisory meeting... and perhaps application in EU for approval. DBC, Although Hakan and Matt were communicating happiness with Sanofi, obviously Al and the BOD were not so happy, hence the Hakan removal as CEO. What I meant about "negotiations" has to do with the activities of the Afrezza JV and the resources being allocated to it by Sanofi. I expect the Mannkind will demand increasing the DTC advertising (television) budget and a beginning a comprehensive public relations effort. Trend |
|
